Drug Repurposing Study Shows Promise for Alzheimer's

A comprehensive review published in Ageing Research Reviews examines the potential of drug repurposing as a promising strategy for Alzheimer's disease (AD) treatment. With over 55 million people affected globally and projections reaching 139 million cases by 2050, researchers are exploring innovative approaches to address the limited effectiveness of current therapies.

What This Study Found

The research review by More et al. analyzed the current landscape of drug repurposing in Alzheimer's disease, identifying several key findings about therapeutic strategies and promising candidates.

The study suggests that existing approved therapies, including cholinesterase inhibitors and NMDA receptor antagonists, provide only symptomatic relief rather than addressing underlying disease mechanisms. Researchers found that recently approved anti-amyloid monoclonal antibodies demonstrate low clinical efficacy while presenting safety and cost concerns.

According to the review, drug repurposing offers a viable alternative by utilizing medications with established safety profiles to accelerate therapeutic discovery. The researchers identified several categories of repurposed agents targeting diverse pathological pathways:

Antidiabetic agents such as metformin and GLP-1 receptor agonists showed potential in addressing metabolic dysfunction associated with Alzheimer's disease. The study suggests these medications may influence amyloid aggregation and neuroinflammation pathways.

Anti-hypertensive medications like candesartan demonstrated neuroprotective properties, while anti-inflammatory drugs including NSAIDs and pioglitazone targeted neuroinflammation processes central to AD progression.

Notably, the research highlighted mitochondrial dysfunction as a significant early factor in Alzheimer's development. The study identified several mitochondria-targeted therapeutics as promising disease-modifying options, including SS-31, Mdivi-1, MitoQ, DDQ, and SkQ1.

Researchers found that artificial intelligence, multi-omics approaches, and precision medicine technologies are enhancing drug repurposing strategies, potentially improving the identification and development of effective treatments.

Clinical Significance

The clinical implications of this research review are substantial for the Alzheimer's disease treatment landscape. The study suggests that the multifactorial nature of AD pathophysiology—characterized by amyloid-β plaque deposition, tau hyperphosphorylation, synaptic dysfunction, neuroinflammation, and oxidative stress—requires multi-target therapeutic approaches.

Traditional drug development for neurodegenerative diseases faces significant challenges, with high failure rates in clinical trials and lengthy development timelines. The research indicates that drug repurposing could address these limitations by leveraging medications with known safety profiles and established pharmacokinetic properties.

The emphasis on mitochondrial-targeted therapies represents a paradigm shift in Alzheimer's treatment strategy. The study suggests that addressing mitochondrial dysfunction early in disease progression could potentially modify disease course rather than merely treating symptoms.

Researchers noted that the integration of advanced technologies, including AI-driven drug discovery and precision medicine approaches, could enhance the identification of optimal repurposing candidates and patient selection strategies.

Current Access and Compliance Context

The drug repurposing approach presents unique considerations for clinical implementation and patient access. Many of the identified candidates are already approved medications for other conditions, potentially facilitating off-label use under appropriate medical supervision.

However, the study emphasizes that repurposed medications require rigorous clinical evaluation specifically for Alzheimer's disease applications. While these drugs have established safety profiles for their original indications, their use in AD populations may present different risk-benefit considerations.

The research suggests that regulatory pathways for repurposed medications may offer advantages over novel drug development, potentially reducing time to market and development costs. This could improve patient access to innovative treatments while maintaining safety standards.

Healthcare providers considering repurposed medications for Alzheimer's patients must carefully evaluate individual patient factors, including comorbidities, concurrent medications, and specific disease characteristics.

What Patients Should Know

Patients and families affected by Alzheimer's disease should understand that this research represents an evolving area of investigation rather than immediately available treatments. The study suggests promising directions for future therapeutic development but does not establish definitive treatment recommendations.

The multi-target approach highlighted in the research indicates that future Alzheimer's treatments may involve combination therapies addressing multiple disease pathways simultaneously. This could potentially improve treatment outcomes compared to single-target approaches.

Patients should be aware that mitochondrial-targeted therapies, while promising in research settings, require further clinical validation before becoming standard treatment options. The study emphasizes the importance of continued research to establish efficacy and safety in human populations.

Those interested in participating in clinical trials for repurposed medications should discuss opportunities with their healthcare providers, as such studies may provide access to innovative treatments while contributing to research advancement.

The research underscores the importance of comprehensive care approaches that may incorporate lifestyle interventions alongside pharmacological treatments, as some repurposed medications target metabolic and cardiovascular pathways that influence brain health.

Conclusion

This comprehensive review highlights the potential of drug repurposing as a valuable strategy for addressing the urgent need for effective Alzheimer's disease treatments. The study suggests that targeting multiple pathological pathways through repurposed medications, particularly those addressing mitochondrial dysfunction, could offer new hope for patients and families affected by this devastating condition.

While these findings represent important progress in Alzheimer's research, continued clinical investigation is essential to establish the safety and efficacy of repurposed therapies in AD populations. The integration of advanced technologies and precision medicine approaches may further enhance the success of these innovative treatment strategies.

For patients seeking expert guidance on the latest Alzheimer's treatment approaches and clinical trial opportunities, consult with qualified healthcare providers at peptideassociation.org/find-a-doctor.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Patients should consult qualified healthcare providers for personalized treatment recommendations and clinical guidance.

Citation: More PS, Rangari SW, Lade SN, et al. Drug Repurposing in Alzheimer's Disease: Emerging Therapeutic Strategies and Promising Candidates. Ageing Res Rev. 2026;103113. doi:10.1016/j.arr.2026.103113